{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:30:50Z","timestamp":1786465850164,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-02059"],"award-info":[{"award-number":["2021-02059"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40262-026-01664-y","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:39:08Z","timestamp":1782715148000},"page":"1257-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-2128","authenticated-orcid":false,"given":"Haini","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6112-2971","authenticated-orcid":false,"given":"Muhammad Waqas","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-2417","authenticated-orcid":false,"given":"Markus","family":"Frid\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-6186","authenticated-orcid":false,"given":"Jens M.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-6445","authenticated-orcid":false,"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1664_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67\u201374. https:\/\/doi.org\/10.1038\/nrd2153.","journal-title":"Nat Rev Drug Discov"},{"key":"1664_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2732017","volume":"2018","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:1. https:\/\/doi.org\/10.1155\/2018\/2732017.","journal-title":"Can Respir J"},{"key":"1664_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/psp4.12344","volume":"7","author":"E Boger","year":"2018","unstructured":"Boger E, Wigstr\u00f6m O. A partial differential equation approach to inhalation physiologically based pharmacokinetic modeling. CPT Pharmacometr Syst Pharmacol. 2018;7:638\u201346. https:\/\/doi.org\/10.1002\/psp4.12344.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1664_CR4","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1111\/bph.15621","volume":"178","author":"MW Sadiq","year":"2021","unstructured":"Sadiq MW, Holz O, Ellinghusen BD, Faulenbach C, M\u00fcller M, Badorrek P, et al. Lung pharmacokinetics of inhaled and systemic drugs: a clinical evaluation. Br J Pharmacol. 2021;178:4440\u201351. https:\/\/doi.org\/10.1111\/bph.15621.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1664_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2007","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2007;61(2):235\u20137. https:\/\/doi.org\/10.1093\/jac\/dkm476.","journal-title":"J Antimicrob Chemother"},{"key":"1664_CR6","doi-asserted-by":"publisher","first-page":"L807","DOI":"10.1152\/ajplung.00054.2024","volume":"327","author":"S Haeger","year":"2024","unstructured":"Haeger S, Moore CM, McManus SA, Moore PK, Janssen WJ, Mould KJ. The bronchoalveolar lavage dilution conundrum: an updated view on a long-standing problem. Am J Physiol Lung Cell Mol Physiol. 2024;327:L807\u201313. https:\/\/doi.org\/10.1152\/ajplung.00054.2024.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1664_CR7","doi-asserted-by":"publisher","DOI":"10.2165\/11594090-000000000-00000","author":"KA Rodvold","year":"2011","unstructured":"Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid. Clin Pharmacokinet. 2011. https:\/\/doi.org\/10.2165\/11594090-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1664_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometr Syst Pharmacol. 2012;1:e6. https:\/\/doi.org\/10.1038\/psp.2012.4.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1664_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-020-00971-2","volume":"60","author":"SW van Beek","year":"2021","unstructured":"van Beek SW, Ter Heine R, Alffenaar J-WC, Magis-Escurra C, Aarnoutse RE, Svensson EM, et al. A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis. Clin Pharmacokinet. 2021;60:943\u201353. https:\/\/doi.org\/10.1007\/s40262-020-00971-2.","journal-title":"Clin Pharmacokinet"},{"key":"1664_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.xphs.2018.09.017","volume":"108","author":"T Sou","year":"2019","unstructured":"Sou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. Model-based drug development in pulmonary delivery: pharmacokinetic analysis of novel drug candidates for treatment of Pseudomonas aeruginosa lung infection. J Pharm Sci. 2019;108:630\u201340. https:\/\/doi.org\/10.1016\/j.xphs.2018.09.017.","journal-title":"J Pharm Sci"},{"key":"1664_CR11","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1128\/AAC.03510-14","volume":"58","author":"M Boisson","year":"2014","unstructured":"Boisson M, Jacobs M, Gr\u00e9goire N, Gobin P, Marchand S, Couet W, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58:7331\u20139. https:\/\/doi.org\/10.1128\/AAC.03510-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1664_CR12","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1093\/jac\/dky239","volume":"73","author":"M Boisson","year":"2018","unstructured":"Boisson M, Mimoz O, Hadzic M, Marchand S, Adier C, Couet W, et al. Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients. J Antimicrob Chemother. 2018;73:2830\u20137. https:\/\/doi.org\/10.1093\/jac\/dky239.","journal-title":"J Antimicrob Chemother"},{"key":"1664_CR13","doi-asserted-by":"publisher","first-page":"e00973","DOI":"10.1128\/AAC.00973-17","volume":"61","author":"Y-W Lin","year":"2017","unstructured":"Lin Y-W, Zhou QT, Hu Y, Onufrak NJ, Sun S, Wang J, et al. Pulmonary pharmacokinetics of colistin following administration of dry powder aerosols in Rats. Antimicrob Agents Chemother. 2017;61:e00973-e1017. https:\/\/doi.org\/10.1128\/AAC.00973-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1664_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometr Syst Pharmacol. 2013;2:63. https:\/\/doi.org\/10.1038\/psp.2013.41.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1664_CR15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00134-009-1417-4","volume":"35","author":"O Baldesi","year":"2009","unstructured":"Baldesi O, Michel F, Guervilly C, Embriaco N, Granfond A, La Scola B, et al. Bacterial ventilator-associated pneumonia: bronchoalveolar lavage results are not influenced by dilution. Intensive Care Med. 2009;35:1210\u20135. https:\/\/doi.org\/10.1007\/s00134-009-1417-4.","journal-title":"Intensive Care Med"},{"key":"1664_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","volume":"10","author":"DJ Irby","year":"2021","unstructured":"Irby DJ, Ibrahim ME, Dauki AM, Badawi MA, Illamola SM, Chen M, et al. Approaches to handling missing or \u201cproblematic\u201d pharmacology data: Pharmacokinetics. CPT Pharmacomet Syst Pharmacol. 2021;10:291\u2013308. https:\/\/doi.org\/10.1002\/psp4.12611.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"1664_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/psp4.12773","volume":"11","author":"P Courlet","year":"2022","unstructured":"Courlet P, Buclin T, Biollaz J, Mazzoni I, Rabin O, Guidi M. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. CPT Pharmacometr Syst Pharmacol. 2022;11:469\u201381. https:\/\/doi.org\/10.1002\/psp4.12773.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1664_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13316","author":"H Wen","year":"2025","unstructured":"Wen H, Sadiq MW, Friberg LE, Svensson EM. Translational physiologically based pharmacokinetic modeling to predict human pulmonary kinetics after lung delivery. CPT Pharmacomet Syst Pharmacol. 2025. https:\/\/doi.org\/10.1002\/psp4.13316.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1664_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/978-3-642-87553-3_10","volume-title":"Morphometry of the human lung [Internet]","author":"ER Weibel","year":"1963","unstructured":"Weibel ER. Geometry and dimensions of airways of conductive and transitory zones. In: Weibel ER, editor. Morphometry of the human lung [Internet]. Berlin: Springer; 1963. p. 110\u201335. https:\/\/doi.org\/10.1007\/978-3-642-87553-3_10."},{"key":"1664_CR20","unstructured":"MPPD: multiple-path particle dosimetry model\u2014ARA [Internet]. 2020 [cited 2023 Aug 6]. https:\/\/www.ara.com\/mppd\/. Accessed 6 Aug 2023."},{"key":"1664_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10928-016-9468-y","volume":"43","author":"S Ueckert","year":"2016","unstructured":"Ueckert S, Karlsson MO, Hooker AC. Accelerating Monte Carlo power studies through parametric power estimation. J Pharmacokinet Pharmacodyn. 2016;43:223\u201334. https:\/\/doi.org\/10.1007\/s10928-016-9468-y.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1664_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12248-010-9248-3","volume":"13","author":"KE Karlsson","year":"2011","unstructured":"Karlsson KE, Plan EL, Karlsson MO. Performance of three estimation methods in repeated time-to-event modeling. AAPS J. 2011;13:83\u201391. https:\/\/doi.org\/10.1208\/s12248-010-9248-3.","journal-title":"AAPS J"},{"key":"1664_CR23","unstructured":"Commissioner O of the. Assessment of Drug Permeability using the Emulate Lung Microphysiological System [Internet]. FDA. FDA; 2023 [cited 2025 Feb 23]. https:\/\/www.fda.gov\/science-research\/fda-science-forum\/assessment-drug-permeability-using-emulate-lung-microphysiological-system. Accessed 23 Feb 2025."},{"key":"1664_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/acs.molpharmaceut.3c00685","volume":"21","author":"JE Hastedt","year":"2023","unstructured":"Hastedt JE, B\u00e4ckman P, Cabal A, Clark A, Ehrhardt C, Forbes B, et al. iBCS: 3. A biopharmaceutics classification system for orally inhaled drug products. Mol Pharm. 2023;21:164\u201372. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00685.","journal-title":"Mol Pharm"},{"key":"1664_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/978-0-387-74901-3_18","volume-title":"Drug absorption studies in situ, in vitro and in silico models [Internet]","author":"C Li","year":"2008","unstructured":"Li C, Wainhaus S, Uss AS, Cheng K-C. High-throughput screening using Caco-2 cell and PAMPA systems. In: Ehrhardt C, Kim K-J, editors. Drug absorption studies in situ, in vitro and in silico models [Internet]. Boston: Springer US; 2008. p. 418\u201329. https:\/\/doi.org\/10.1007\/978-0-387-74901-3_18."},{"key":"1664_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1021\/acs.molpharmaceut.4c00975","volume":"22","author":"K Storchmannov\u00e1","year":"2025","unstructured":"Storchmannov\u00e1 K, Balouch M, Jura\u010dka J, \u0160t\u011bp\u00e1nek F, Berka K. Meta-analysis of permeability literature data shows possibilities and limitations of popular methods. Mol Pharm. 2025;22:1293\u2013304. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00975.","journal-title":"Mol Pharm"},{"key":"1664_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0169-7439(99)00027-1","volume":"49","author":"N (Klaas)M Faber","year":"1999","unstructured":"Faber N (Klaas)M. Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibration. Chemom Intell Lab Syst. 1999;49:79\u201389. https:\/\/doi.org\/10.1016\/S0169-7439(99)00027-1.","journal-title":"Chemom Intell Lab Syst"},{"key":"1664_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fphar.2020.00172","volume":"11","author":"D Alihodzic","year":"2020","unstructured":"Alihodzic D, Broeker A, Baehr M, Kluge S, Langebrake C, Wicha SG. Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing. Front Pharmacol. 2020;11:172. https:\/\/doi.org\/10.3389\/fphar.2020.00172.","journal-title":"Front Pharmacol"},{"key":"1664_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacomet Syst Pharmacol. 2019;8:525\u201337. https:\/\/doi.org\/10.1002\/psp4.12404.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"1664_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"R Keizer","year":"2013","unstructured":"Keizer R, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometr Syst Pharmacol. 2013;2:50. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"1664_CR31","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2025 Feb 23]. https:\/\/www.r-project.org\/. Accessed 23 Feb 2025."},{"key":"1664_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1183\/09031936.99.13367399","volume":"13","author":"F Pierart","year":"1999","unstructured":"Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Souef PL. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J. 1999;13:673\u20138. https:\/\/doi.org\/10.1183\/09031936.99.13367399.","journal-title":"Eur Respir J"},{"key":"1664_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10928-015-9449-6","volume":"42","author":"AN Kristoffersson","year":"2015","unstructured":"Kristoffersson AN, Friberg LE, Nyberg J. Inter occasion variability in individual optimal design. J Pharmacokinet Pharmacodyn. 2015;42:735\u201350. https:\/\/doi.org\/10.1007\/s10928-015-9449-6.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1664_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1208\/s12248-015-9760-6","volume":"17","author":"JM Borghardt","year":"2015","unstructured":"Borghardt JM, Weber B, Staab A, Kloft C. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J. 2015;17:853\u201370. https:\/\/doi.org\/10.1208\/s12248-015-9760-6.","journal-title":"AAPS J"},{"key":"1664_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jamp.2017.1436","volume":"32","author":"E Boger","year":"2019","unstructured":"Boger E, Frid\u00e9n M. Physiologically based pharmacokinetic\/pharmacodynamic modeling accurately predicts the better bronchodilatory effect of inhaled versus oral salbutamol dosage forms. J Aerosol Med Pulm Drug Deliv. 2019;32:1\u201312. https:\/\/doi.org\/10.1089\/jamp.2017.1436.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1664_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106588","volume":"59","author":"A Gkoufa","year":"2022","unstructured":"Gkoufa A, Sou T, Karaiskos I, Routsi C, Lin Y-W, Psichogiou M, et al. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia. Int J Antimicrob Agents. 2022;59:106588. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106588.","journal-title":"Int J Antimicrob Agents"},{"key":"1664_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107293","volume":"64","author":"P Ding","year":"2024","unstructured":"Ding P, Li H, Nan Y, Liu C, Wang G, Cai H, et al. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2024;64:107293. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107293.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01664-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:17:10Z","timestamp":1786461430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01664-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.W., M.W.S., M.F., L.E.F., and E.M.S. wrote the manuscript; H.W., L.E.F., and E.M.S. designed the research; H.W., M.W.S., M.F., L.E.F., and E.M.S. performed the research; M.W.S. and J.M.H. contributed to data acquisition and data interpretation; H.W. analysed the data; L.E.F. and E.M.S. contributed analytical tools. All authors have read and approved the final version of the manuscript.","order":1,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.W.S. and M.F. are employed by AstraZeneca. All other authors declare no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The dataset analysed in this study was obtained from a previously published source (ClinicalTrials.gov Identifier: NCT03524066). Access to the data is subject to AstraZeneca\u2019s data sharing policy, available at\u00a0\n                      \n                      .","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model code is available within the supplemental materials.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for participation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}